ev3’s Protégé Joins Sprouting Field In U.S. Carotid Stent Market
This article was originally published in The Gray Sheet
Executive Summary
Plymouth, Minn.-based ev3 Inc. joined a growing number of players in the U.S. carotid stent market with the Jan. 25 nationwide launch of its Protégé RX immediately following FDA approval
You may also be interested in...
Boston Scientific acquires EndoTex
Boston Scientific acquires NexStent carotid stent maker EndoTex International Jan. 4 following PMA approval of the device Oct. 27 (1"The Gray Sheet" Nov. 13, 2006, In Brief). While terms of the deal were not disclosed, Boston Scientific told the Securities and Exchange Commission it expected to pay about $100 million for the company, mostly in stock, on top of $40 million it had already invested, plus future milestone payments. NexStent has been distributed exclusively by Boston Scientific outside the United States since 2005. The device is intended for use with Boston Scientific's FilterWire EZ embolic protection system for carotid revascularization of patients at high risk for adverse events from carotid endarterectomy (2"The Gray Sheet" Dec. 18, 2006, In Brief)...
Carotid Stent Firms See Another Step Into Market With Expanded Coverage
Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.